SMAD4 and familial pancreatic carcinoma: More recently, Jung and coworkers reported the successful growth in 72% of cases of primary human pancreatic cancer specimens injected subcutaneously into NOD/SCID mice [179]; importantly, the xenografts conserved a pattern of TP53 and SMAD4 expression like the original tumor [179].